Analysts see biopharma climbing after Democratic 'blue wave' as drug pricing takes back seat
Historical midterm patterns and expectations that Democrats will prioritize other fights over drug pricing underpin the bullish read.
Read at Biopharmadive →Full coverage · 7 outlets
- Biopharmadive · lead
- STATSTAT+: Five midterm winners and losers: MAHA mowed down, Dem docs scrub in, ‘Medicare for All’ returns
- Yahoo FinanceBiopharma likely to climb higher after ‘blue wave,’ analysts say
- BioSpaceWith MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
- MarketWatchHospital stocks rallied while drugmakers brace for scrutiny. Here’s what the Democratic wave means for healthcare.
- BioPharma DiveA hidden tradeoff in Trump’s drug pricing deals
- YahooBiopharma likely to climb higher after ‘blue wave,’ analysts say